Daniela D Berg

List of Publications by Citations

557 papers	34,080 citations	91 h-index	169 g-index
589 ext. papers	40,971 ext. citations	5.9 avg, IF	6.93 L-index

#	Paper	IF	Citations
557	MDS clinical diagnostic criteria for Parkinson's disease. *Movement Disorders*, **2015**, 30, 1591-601	7	2371
556	Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nature Genetics* , **2009**, 41, 1308-12	36.3	1469
555	Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. *New England Journal of Medicine*, **2009**, 361, 1651-61	59.2	1351
554	The Parkinson Progression Marker Initiative (PPMI). *Progress in Neurobiology*, **2011**, 95, 629-35	10.9	793
553	Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet, The*, **2011**, 377, 641-9	40	733
552	MDS research criteria for prodromal Parkinson's disease. *Movement Disorders*, **2015**, 30, 1600-11	7	645
551	Differentiation between intracerebral hemorrhage and ischemic stroke by transcranial color-coded duplex-sonography. *Stroke*, **1998**, 29, 2563-7	6.7	583
550	Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. *Nature Genetics*, **2001**, 29, 66-9	36.3	458
549	Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. *Human Molecular Genetics*, **2005**, 14, 2099-111	5.6	446
548	Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. *Journal of Neuroscience*, **2007**, 27, 12413-8	6.6	431
547	Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. *PLoS Genetics*, **2012**, 8, e1002548	6	420
546	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nature Genetics*, **2011**, 43, 699-705	36.3	386
545	Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. *Cell Stem Cell*, **2013**, 12, 354-67	18	382
544	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. *Movement Disorders*, **2017**, 32, 1264-1310	7	375
543	Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. *Archives of Neurology*, **2002**, 59, 999-1005		366
542	14-3-3 proteins in the nervous system. *Nature Reviews Neuroscience*, **2003**, 4, 752-62	13.5	350
541	iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. *Nature Communications*, **2014**, 5, 4028	17.4	324

540	EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease. *European Journal of Neurology*, **2013**, 20, 16-34	6	299
539	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. *Movement Disorders*, **2014**, 29, 454-62	7	290
538	Transcranial sonography in movement disorders. *Lancet Neurology, The*, **2008**, 7, 1044-55	24.1	290
537	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. *JAMA Neurology*, **2013**, 70, 727-35	17.2	285
536	Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 2626-31	11.5	282
535	Brain iron pathways and their relevance to Parkinson's disease. *Journal of Neurochemistry*, **2001**, 79, 225-36	6	275
534	Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. *Journal of Neurology*, **2001**, 248, 684-9	5.5	256
533	Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. *Annals of Neurology*, **1999**, 45, 611-7	9.4	245
532	Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. *Lancet Neurology, The*, **2011**, 10, 898-908	24.1	237
531	Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. *Cell Death and Differentiation*, **2011**, 18, 769-82	12.7	235
530	Genome-wide association study of intracranial aneurysm identifies three new risk loci. *Nature Genetics*, **2010**, 42, 420-5	36.3	234
529	SNCA variants are associated with increased risk for multiple system atrophy. *Annals of Neurology*, **2009**, 65, 610-4	9.4	232
528	Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. *Neurology*, **1999**, 53, 1026-31	6.5	227
527	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. *American Journal of Human Genetics*, **2016**, 98, 500-513	11	225
526	Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. *Brain*, **2005**, 128, 3000-11	11.2	217
525	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. *Brain*, **2017**, 140, 3191-3203	11.2	209
524	A two-stage meta-analysis identifies several new loci for Parkinson's disease. *PLoS Genetics*, **2011**, 7, e1002142	6	209
523	Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. *FASEB Journal*, **2008**, 22, 1327-34	0.9	209

522	Progression of Parkinson's disease in the clinical phase: potential markers. *Lancet Neurology, The*, **2009**, 8, 1158-71	24.1	208
521	Multiple regions of alpha-synuclein are associated with Parkinson's disease. *Annals of Neurology*, **2005**, 57, 535-41	9.4	206
520	A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. *Movement Disorders*, **2014**, 29, 470-8	7	201
519	Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. *Movement Disorders*, **2005**, 20, 383-5	7	199
518	The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. *Lancet Neurology, The*, **2008**, 7, 417-24	24.1	195
517	Transcranial brain parenchyma sonography in movement disorders: state of the art. *Ultrasound in Medicine and Biology*, **2007**, 33, 15-25	3.5	195
516	Advances in markers of prodromal Parkinson disease. *Nature Reviews Neurology*, **2016**, 12, 622-634	15	189
515	GBA-associated PD presents with nonmotor characteristics. *Neurology*, **2011**, 77, 276-80	6.5	182
514	Phosphorylated □synuclein in Parkinson's disease. *Science Translational Medicine*, **2012**, 4, 121ra20	17.5	182
513	Role of iron in neurodegenerative disorders. *Topics in Magnetic Resonance Imaging*, **2006**, 17, 5-17	2.3	178
512	In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. *Movement Disorders*, **2005**, 20, 1278-85	7	178
511	Update of the MDS research criteria for prodromal Parkinson's disease. *Movement Disorders*, **2019**, 34, 1464-1470	7	177
510	Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. *Journal of Neuroimmunology*, **2007**, 188, 117-27	3.5	170
509	Relationship of substantia nigra echogenicity and motor function in elderly subjects. *Neurology*, **2001**, 56, 13-7	6.5	167
508	Redox imbalance. *Cell and Tissue Research*, **2004**, 318, 201-13	4.2	160
507	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. *Neurobiology of Disease*, **2009**, 34, 107-12	7.5	158
506	Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 5500-5	11.5	157
505	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*, **2014**, 23, 6139-46	5.6	152

504	Iron accumulation in the substantia nigra in rats visualized by ultrasound. *Ultrasound in Medicine and Biology*, **1999**, 25, 901-4	3.5	150
503	AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. *Movement Disorders*, **2011**, 26, 1243-50	7	147
502	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. *Human Molecular Genetics*, **2012**, 21, 4996-5009	5.6	145
501	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. *Annals of Neurology*, **2011**, 70, 964-73	9.4	144
500	Iron metabolism in Parkinsonian syndromes. *Movement Disorders*, **2006**, 21, 1299-310	7	144
499	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1460-1477	5.3	142
498	GBA-associated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. *Movement Disorders*, **2015**, 30, 407-11	7	135
497	Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. *Archives of Neurology*, **2011**, 68, 932-7		131
496	Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. *Human Molecular Genetics*, **2009**, 18, 3832-50	5.6	130
495	Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain*, **2020**, 143, 3077-3088	11.2	130
494	Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. *NeuroReport*, **2000**, 11, 2079-82	1.7	128
493	Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study. *PLoS ONE*, **2013**, 8, e73094	3.7	124
492	[11C]PIB binding in Parkinson's disease dementia. *NeuroImage*, **2008**, 39, 1027-33	7.9	120
491	Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 423-5	5.5	120
490	S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF- pathway. *Brain*, **2012**, 135, 3336-47	11.2	118
489	Cerebral activation patterns in patients with writer's cramp: a functional magnetic resonance imaging study. *Journal of Neurology*, **2001**, 248, 10-7	5.5	112
488	Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. *Movement Disorders*, **2007**, 22, 187-92	7	111
487	Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. *Neurology*, **2008**, 70, 1456-60	5	109

486	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. *Lancet Neurology, The*, **2013**, 12, 514-24	24.1	108
485	Multiregional brain iron deficiency in restless legs syndrome. *Movement Disorders*, **2008**, 23, 1184-7	7	108
484	The patients' perception of prodromal symptoms before the initial diagnosis of Parkinson's disease. *Movement Disorders*, **2011**, 26, 653-8	7	107
483	Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. *Movement Disorders*, **2014**, 29, 479-87	7	106
482	Large-scale replication and heterogeneity in Parkinson disease genetic loci. *Neurology*, **2012**, 79, 659-67	6.5	106
481	Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). *Human Mutation*, **2004**, 24, 321-9	4.7	104
480	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. *Movement Disorders*, **2018**, 33, 1601-1608	7	101
479	Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. *Neurology*, **2004**, 63, 1912-7	6.5	99
478	Neuroimaging in basal ganglia disorders: perspectives for transcranial ultrasound. *Movement Disorders*, **2001**, 16, 23-32	7	98
477	Depression in Parkinson's disease: brainstem midline alteration on transcranial sonography and magnetic resonance imaging. *Journal of Neurology*, **1999**, 246, 1186-93	5.5	98
476	Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. *Movement Disorders*, **2012**, 27, 656-65	7	96
475	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. *Human Molecular Genetics*, **2013**, 22, 1039-49	5.6	96
474	Health-Related Quality of Life in patients with Parkinson's disease--A systematic review based on the ICF model. *Neuroscience and Biobehavioral Reviews*, **2016**, 61, 26-34	9	95
473	Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy. *Biological Psychiatry*, **2001**, 50, 463-7	7.9	95
472	To rise and to fall: functional connectivity in cognitively normal and cognitively impaired patients with Parkinson's disease. *Neurobiology of Aging*, **2015**, 36, 1727-1735	5.6	94
471	The transcription factor PITX3 is associated with sporadic Parkinson's disease. *Neurobiology of Aging*, **2009**, 30, 731-8	5.6	92
470	The PRIPS study: screening battery for subjects at risk for Parkinson's disease. *European Journal of Neurology*, **2013**, 20, 102-8	6	91
469	Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. *Neurobiology of Disease*, **2007**, 25, 473-82	7.5	91

468	Disturbance of iron metabolism in Parkinson's disease -- ultrasonography as a biomarker. *Neurotoxicity Research*, **2006**, 9, 1-13	4.3	91
467	Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. *NeuroImage*, **2003**, 18, 416-22	7.9	91
466	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. *Movement Disorders*, **2013**, 28, 216-9	7	90
465	Increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia. *Annals of Neurology*, **1999**, 46, 260-3	9.4	86
464	Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. *Neurology*, **2017**, 89, 1959-1969	6.5	84
463	Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. *Journal of Neural Transmission*, **2000**, 107, 553-62	4.3	82
462	Arm swing as a potential new prodromal marker of Parkinson's disease. *Movement Disorders*, **2016**, 31, 1527-1534	7	80
461	Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study. *PLoS Medicine*, **2013**, 10, e1001462	11.6	80
460	Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers. *Neurology*, **2016**, 86, 994-9	6.5	78
459	Prodromal features for Parkinson's disease--baseline data from the TREND study. *European Journal of Neurology*, **2014**, 21, 766-72	6	76
458	Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. *Annals of Neurology*, **2011**, 69, 778-92	9.4	76
457	Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. *Movement Disorders*, **2009**, 24, 2136-42	7	76
456	Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. *Movement Disorders*, **2017**, 32, 1432-1438	7	74
455	The basal ganglia in haemochromatosis. *Neuroradiology*, **2000**, 42, 9-13	3.2	74
454	Biomarkers for the early detection of Parkinson's and Alzheimer's disease. *Neurodegenerative Diseases*, **2008**, 5, 133-6	2.3	72
453	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. *Neurobiology of Aging*, **2015**, 36, 1605.e7-12	5.6	70
452	Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. *Deutsches Ärzteblatt International*, **2013**, 110, 1-7, e1	2.5	70
451	Validation of the MDS research criteria for prodromal Parkinson's disease: Longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. *Movement Disorders*, **2017**, 32, 865-873	7	69

450	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurology, The*, **2015**, 14, 145-52	24.1	69
449	Functional relevance of ceruloplasmin mutations in Parkinson's disease. *FASEB Journal*, **2005**, 19, 1851-3	0.9	68
448	Movement disorder society criteria for clinically established early Parkinson's disease. *Movement Disorders*, **2018**, 33, 1643-1646	7	67
447	The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. *Movement Disorders*, **2017**, 32, 510-525	7	65
446	Iron as a therapeutic target for Parkinson's disease. *Movement Disorders*, **2018**, 33, 568-574	7	65
445	Microglia activation is related to substantia nigra echogenicity. *Journal of Neural Transmission*, **2010**, 117, 1287-92	4.3	64
444	Aging-related cortical reorganization of verbal fluency processing: a functional near-infrared spectroscopy study. *Neurobiology of Aging*, **2013**, 34, 439-50	5.6	63
443	Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. *Movement Disorders*, **2005**, 20, 1191-4	7	63
442	Man-in-the-barrel syndrome caused by cervical spinal cord infarction. *Acta Neurologica Scandinavica*, **1998**, 97, 417-9	3.8	62
441	The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. *Neurobiology of Disease*, **2012**, 45, 356-61	7.5	61
440	The new definition and diagnostic criteria of Parkinson's disease. *Lancet Neurology, The*, **2016**, 15, 546-8	24.1	61
439	Prodromal Parkinson's Disease: The Decade Past, the Decade to Come. *Movement Disorders*, **2019**, 34, 665-675	7	59
438	L-dopa increases Esynuclein DNA methylation in Parkinson's disease patients in vivo and in vitro. *Movement Disorders*, **2015**, 30, 1794-801	7	59
437	miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. *Oncotarget*, **2018**, 9, 17455-17465	3.3	59
436	Poor trail making test performance is directly associated with altered dual task prioritization in the elderly--baseline results from the TREND study. *PLoS ONE*, **2011**, 6, e27831	3.7	58
435	Impaired trunk stability in individuals at high risk for Parkinson's disease. *PLoS ONE*, **2012**, 7, e32240	3.7	58
434	Serum neuronal exosomes predict and differentiate Parkinson's disease from atypical parkinsonism. *Journal of Neurology, Neurosurgery and Psychiatry*, **2020**, 91, 720-729	5.5	57
433	Genome-wide association study in essential tremor identifies three new loci. *Brain*, **2016**, 139, 3163-3169	11.2	57

432	Gait analysis with wearables predicts conversion to parkinson disease. *Annals of Neurology*, **2019**, 86, 357-367	9.4	57
431	Reproducibility and diagnostic accuracy of substantia nigra sonography for the diagnosis of Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 1087-92	5.5	57
430	Basal limbic system alteration in major depression: a hypothesis supported by transcranial sonography and MRI findings. *International Journal of Neuropsychopharmacology*, **2001**, 4, 21-31	5.8	57
429	Transcranial ultrasound in different monogenetic subtypes of Parkinson's disease. *Journal of Neurology*, **2007**, 254, 613-6	5.5	56
428	Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 1099-105	5.5	56
427	Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. *Movement Disorders*, **2011**, 26, 2335-42	7	55
426	Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. *Journal of Neural Transmission*, **2012**, 119, 39-52	4.3	54
425	ATP13A2 variants in early-onset Parkinson's disease patients and controls. *Movement Disorders*, **2009**, 24, 2104-11	7	54
424	Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. *Movement Disorders*, **2008**, 23, 596-9	7	54
423	In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage. *Journal of Neural Transmission*, **2006**, 113, 775-80	4.3	54
422	The correlation between ventricular diameter measured by transcranial sonography and clinical disability and cognitive dysfunction in patients with multiple sclerosis. *Archives of Neurology*, **2000**, 57, 1289-92		54
421	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. *Movement Disorders*, **2017**, 32, 1025-1034	7	53
420	Cognitive changes in prodromal Parkinson's disease: A review. *Movement Disorders*, **2017**, 32, 1655-1666	7	53
419	Synuclein in Parkinson's disease: causal or bystander?. *Journal of Neural Transmission*, **2019**, 126, 815-840	4.3	53
418	Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease. *Movement Disorders*, **2017**, 32, 1401-1408	7	53
417	Characterizing POLG ataxia: clinics, electrophysiology and imaging. *Cerebellum*, **2012**, 11, 1002-11	4.3	53
416	Genetics and iron in the systems biology of Parkinson's disease and some related disorders. *Neurochemistry International*, **2013**, 62, 637-52	4.4	53
415	Identification of novel Angiogenin (ANG) gene missense variants in German patients with amyotrophic lateral sclerosis. *Journal of Neurology*, **2009**, 256, 1337-42	5.5	53

414	Motor dual-tasking deficits predict falls in Parkinson's disease: A prospective study. *Parkinsonism and Related Disorders*, **2016**, 26, 73-7	3.6	53
413	In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. *Neurobiology of Disease*, **2016**, 91, 59-68	7.5	52
412	Sonographic abnormalities of brainstem structures in restless legs syndrome. *Sleep Medicine*, **2008**, 9, 782-9	4.6	51
411	Predictive value of transcranial sonography in the diagnosis of Parkinson's disease. *Movement Disorders*, **2006**, 21, 1763-5	7	51
410	MicroRNA-101 Regulates Multiple Developmental Programs to Constrain Excitation in Adult Neural Networks. *Neuron*, **2016**, 92, 1337-1351	13.9	50
409	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiology of Aging*, **2016**, 38, 214.e7-214.e10	5.6	49
408	Genetic comorbidities in Parkinson's disease. *Human Molecular Genetics*, **2014**, 23, 831-41	5.6	49
407	Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. *Neurology*, **2004**, 62, 1231-2	6.5	49
406	Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica. *Journal of Neural Transmission*, **1999**, 106, 725-8	4.3	49
405	Longitudinal analyses of cerebrospinal fluid □Synuclein in prodromal and early Parkinson's disease. *Movement Disorders*, **2019**, 34, 1354-1364	7	48
404	Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias. *Journal of Alzheimer's Disease*, **2011**, 26, 171-9	4.3	48
403	Specification of 14-3-3 proteins in Lewy bodies. *Annals of Neurology*, **2003**, 54, 135	9.4	48
402	Early natural course of transient encephalopathy after coronary artery bypass grafting. *Critical Care Medicine*, **2000**, 28, 1808-11	1.4	48
401	Changes of copper-transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult-onset dystonia. *Annals of Neurology*, **2000**, 47, 827-830	9.4	48
400	Common variants of LRRK2 are not associated with sporadic Parkinson's disease. *Annals of Neurology*, **2005**, 58, 905-8	9.4	47
399	14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta. *Molecular Brain Research*, **2002**, 108, 33-9		47
398	Inherited Myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families. *Annals of Neurology*, **2001**, 49, 121-4	9.4	45
397	Perspectives of B-mode transcranial ultrasound. *NeuroImage*, **2002**, 15, 463-73	7.9	45

396	A critique of the second consensus criteria for multiple system atrophy. *Movement Disorders*, **2019**, 34, 975-984	7	44
395	Validating Alzheimer's disease micro RNAs using next-generation sequencing. *Alzheimer's and Dementia*, **2016**, 12, 565-76	1.2	44
394	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. *Frontiers in Neurology*, **2017**, 8, 457	4.1	43
393	Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. *NeuroImage*, **2009**, 47, 1237-43	7.9	43
392	Application of transcranial sonography in extrapyramidal disorders: updated recommendations. *Ultraschall in Der Medizin*, **2006**, 27, 12-9	3.8	43
391	Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. *Neuroscience Letters*, **2003**, 352, 53-6	3.3	43
390	Prodromal Parkinson disease subtypes - key to understanding heterogeneity. *Nature Reviews Neurology*, **2021**, 17, 349-361	15	43
389	Promising Metabolite Profiles in the Plasma and CSF of Early Clinical Parkinson's Disease. *Frontiers in Aging Neuroscience*, **2018**, 10, 51	5.3	42
388	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. *Lancet Neurology, The*, **2019**, 18, 724-735	24.1	42
387	Psychopathological symptoms of depression in Parkinson's disease compared to major depression. *Psychopathology*, **2003**, 36, 221-5	3.4	42
386	Quality of life in patients with blepharospasm. *Acta Neurologica Scandinavica*, **2001**, 103, 49-52	3.8	42
385	Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 536-8	5.5	41
384	The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. *FASEB Journal*, **2007**, 21, 1759-67	0.9	41
383	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. *Movement Disorders*, **2015**, 30, 1885-92	7	40
382	The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 666-73	5.5	40
381	Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET. *Movement Disorders*, **2009**, 24, 1504-11	7	40
380	Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. *Acta Neurochirurgica*, **2010**, 152, 2153-60	3	40
379	Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. *Neurology*, **2008**, 70, 1501-3	6.5	40

378	Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms. *Neurochemical Research*, **2007**, 32, 1646-54	4.6	40
377	Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease. *CNS Drugs*, **2014**, 28, 1155-84	6.7	39
376	Transcranial sonography findings related to non-motor features of Parkinson's disease. *Journal of the Neurological Sciences*, **2010**, 289, 123-7	3.2	38
375	Substantia nigra hyperechogenicity as a marker of predisposition and slower progression in Parkinson's disease. *Movement Disorders*, **2006**, 21, 94-8	7	38
374	Transcranial sonography of the brain parenchyma: comparison of B-mode imaging and tissue harmonic imaging. *Ultrasound in Medicine and Biology*, **2000**, 26, 189-94	3.5	38
373	Machine Learning to Detect Alzheimer's Disease from Circulating Non-coding RNAs. *Genomics, Proteomics and Bioinformatics*, **2019**, 17, 430-440	6.5	38
372	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. *Journal of Neural Transmission*, **2015**, 122, 419-25	4.3	37
371	Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-pathway. *Journal of Alzheimer's Disease*, **2011**, 27, 119-26	4.3	37
370	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. *Movement Disorders*, **2010**, 25, 1464-9	7	37
369	Validation of conversion between mini-mental state examination and montreal cognitive assessment. *Movement Disorders*, **2016**, 31, 593-6	7	37
368	GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. *Neurology*, **2012**, 79, 213-20	6.5	36
367	Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. *Movement Disorders*, **2011**, 26, 176-81	7	36
366	Valsalva manoeuvre in patients with different Parkinsonian disorders. *Journal of Neural Transmission*, **2009**, 116, 875-80	4.3	36
365	Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. *Journal of Neural Transmission*, **2008**, 115, 1527-36	4.3	36
364	Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. *PLoS ONE*, **2013**, 8, e56438	3.7	36
363	Vascular Risk Factors and Cognition in Parkinson's Disease. *Journal of Alzheimer's Disease*, **2016**, 51, 563-70	4.3	36
362	Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population. *Neurobiology of Aging*, **2011**, 32, 1599-606	5.6	35
361	Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. *Journal of Neural Transmission*, **2011**, 118, 453-61	4.3	35

360	Parkinson's disease and dementia: a longitudinal study (DEMPARK). *Neuroepidemiology*, **2011**, 37, 168-76	5.4	35
359	Effect of 6-hydroxydopamine (6-OHDA) on proliferation of glial cells in the rat cortex and striatum: evidence for de-differentiation of resident astrocytes. *Cell and Tissue Research*, **2010**, 342, 147-60	4.2	35
358	Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. *Journal of Neural Transmission*, **2010**, 117, 69-76	4.3	35
357	Cross-sectional study discloses a positive family history for Parkinson's disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity. *Journal of Neural Transmission*, **2007**, 114, 1167-71	4.3	35
356	Abolishing the 1-year rule: How much evidence will be enough?. *Movement Disorders*, **2016**, 31, 1623-1627	7	35
355	Screening for prodromal Parkinson's disease in the general community: a sleep-based approach. *Sleep Medicine*, **2016**, 21, 101-5	4.6	34
354	Evidence for disturbances of copper metabolism in dystonia: from the image towards a new concept. *Neurology*, **2001**, 57, 2290-4	6.5	34
353	Alterations in Blood Monocyte Functions in Parkinson's Disease. *Movement Disorders*, **2019**, 34, 1711-1721	7	33
352	Serum insulinlike growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. *Archives of Neurology*, **2011**, 68, 925-31		33
351	Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. *Movement Disorders*, **2010**, 25, 315-24	7	33
350	Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. *Neuroscience Letters*, **2006**, 407, 16-9	3.3	33
349	Inflammatory profile in LRRK2-associated prodromal and clinical PD. *Journal of Neuroinflammation*, **2016**, 13, 122	10.1	33
348	The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. *Journal of Medical Genetics*, **2006**, 43, 557-62	5.8	32
347	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. *Annals of Neurology*, **2020**, 88, 320-331	9.4	32
346	State-dependent altered connectivity in late-life depression: a functional near-infrared spectroscopy study. *Neurobiology of Aging*, **2016**, 39, 57-68	5.6	31
345	Analysis of ACTA2 in European Moyamoya disease patients. *European Journal of Paediatric Neurology*, **2011**, 15, 117-22	3.8	31
344	Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: Clinical observations as a basis for power calculations and safety analysis. *Alzheimer's and Dementia*, **2010**, 6, 70-4	1.2	31
343	Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. *Zeitschrift Fur Gerontologie Und Geriatrie*, **2010**, 43, 224-8	2.7	31

342	Iron in neurodegenerative disorders. *Neurotoxicity Research*, **2002**, 4, 637-653	4.3	31
341	Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. *European Journal of Neurology*, **2017**, 24, 427-e6	6	30
340	Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. *Journal of Neurology*, **2016**, 263, 558-74	5.5	30
339	Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease. *CNS Drugs*, **2017**, 31, 551-570	6.7	30
338	Autonomic dysfunction in different subtypes of multiple system atrophy. *Movement Disorders*, **2008** , 23, 1766-72	7	30
337	The association between alterations of eye movement control and cerebral intrinsic functional connectivity in Parkinson's disease. *Brain Imaging and Behavior*, **2016**, 10, 79-91	4.1	29
336	Metabolomic Profiles for Primary Progressive Multiple Sclerosis Stratification and Disease Course Monitoring. *Frontiers in Human Neuroscience*, **2018**, 12, 226	3.3	29
335	Risk factors and prodromal markers and the development of Parkinson's disease. *Journal of Neurology*, **2014**, 261, 180-7	5.5	29
334	The New Diagnostic Criteria for Parkinson's Disease. *International Review of Neurobiology*, **2017**, 132, 55-78	4.4	29
333	Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. *Acta Neurologica Scandinavica*, **2013**, 127, 362-70	3.8	29
332	Influence of different cut-off values on the diagnosis of mild cognitive impairment in Parkinson's disease. *Parkinson's Disease*, **2011**, 2011, 540843	2.6	29
331	Transcranial ultrasound as a risk marker for Parkinson's disease. *Movement Disorders*, **2009**, 24 Suppl 2, S677-83	7	29
330	Comparable autoantibody serum levels against amyloid- and inflammation-associated proteins in Parkinson's disease patients and controls. *PLoS ONE*, **2014**, 9, e88604	3.7	28
329	Use of support vector machines for disease risk prediction in genome-wide association studies: concerns and opportunities. *Human Mutation*, **2012**, 33, 1708-18	4.7	28
328	SNCA: major genetic modifier of age at onset of Parkinson's disease. *Movement Disorders*, **2013**, 28, 1217-21	7	28
327	Transcranial sonography in spinocerebellar ataxia type 3. *Journal of Neural Transmission Supplementum*, **2004**, 123-33		28
326	Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria. *Journal of Inherited Metabolic Disease*, **2019**, 42, 398-406	5.4	27
325	Consensus for the measurement of the camptocormia angle in the standing patient. *Parkinsonism and Related Disorders*, **2018**, 52, 1-5	3.6	27

324	Friedreich ataxia: dysarthria profile and clinical data. *Cerebellum*, **2013**, 12, 475-84	4.3	27
323	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 171-179	5.5	27
322	TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study. *Parkinsonism and Related Disorders*, **2015**, 21, 306-9	3.6	26
321	The significance of GBA for Parkinson's disease. *Journal of Inherited Metabolic Disease*, **2014**, 37, 643-8	5.4	26
320	Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism. *Movement Disorders*, **2012**, 27, 151-5	7	26
319	The influence of Nordic Walking training on sit-to-stand transfer in Parkinson patients. *Gait and Posture*, **2011**, 34, 234-8	2.6	26
318	In vivo comparison of Richardson's syndrome and progressive supranuclear palsy-parkinsonism. *Journal of Neural Transmission*, **2011**, 118, 1191-7	4.3	26
317	The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. *Journal of Alzheimer's Disease*, **2010**, 19, 937-42	4.3	26
316	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. *Parkinsonism and Related Disorders*, **2009**, 15, 539-41	3.6	26
315	Autonomic dysfunction in patients with progressive supranuclear palsy. *Movement Disorders*, **2008**, 23, 2083-9	7	26
314	Postnatal decrease in substantia nigra echogenicity. Implications for the pathogenesis of Parkinson's disease. *Journal of Neurology*, **2004**, 251, 1451-4	5.5	26
313	Cerebral activation pattern in primary writing tremor. *Journal of Neurology, Neurosurgery and Psychiatry*, **2000**, 69, 780-6	5.5	26
312	Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls. *Journal of Neurology, Neurosurgery and Psychiatry*, **2015**, 86, 32-7	5.5	25
311	Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. *Neurobiology of Aging*, **2014**, 35, 1512.e5-1512.e10	5.6	25
310	Mutation analysis of the neurofilament M gene in Parkinson's disease. *Neuroscience Letters*, **2003**, 351, 125-9	3.3	25
309	Self-reported physical activity levels and clinical progression in early Parkinson's disease. *Parkinsonism and Related Disorders*, **2019**, 61, 118-125	3.6	25
308	Continuous leg dyskinesia assessment in Parkinson's disease -clinical validity and ecological effect. *Parkinsonism and Related Disorders*, **2016**, 26, 41-6	3.6	24
307	Associations between Early Markers of Parkinson's Disease and Sarcopenia. *Frontiers in Aging Neuroscience*, **2017**, 9, 53	5.3	24

306	Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. *Journal of Neural Transmission*, **2012**, 119, 1523-8	4.3	24
305	No association of GBA mutations and multiple system atrophy. *European Journal of Neurology*, **2013**, 20, e61-2	6	24
304	Milestones in magnetic resonance imaging and transcranial sonography of movement disorders. *Movement Disorders*, **2011**, 26, 979-92	7	24
303	Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. *Dementia and Geriatric Cognitive Disorders*, **2011**, 31, 413-6	2.6	24
302	Substantia nigra hyperechogenicity assessed by transcranial sonography is related to neuropsychological impairment in the elderly population. *Journal of Neural Transmission*, **2008**, 115, 993-9	4.3	24
301	Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation. *Journal of Neurology*, **2008**, 255, 643-8	5.5	24
300	Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. *Journal of Neural Transmission*, **2004**, 111, 515-21	4.3	24
299	Quantitative Timed-Up-and-Go Parameters in Relation to Cognitive Parameters and Health-Related Quality of Life in Mild-to-Moderate Parkinson's Disease. *PLoS ONE*, **2016**, 11, e0151997	3.7	24
298	Alpha Synuclein Connects the Gut-Brain Axis in Parkinson's Disease Patients - A View on Clinical Aspects, Cellular Pathology and Analytical Methodology. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 573696	5.7	24
297	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. *Movement Disorders*, **2016**, 31, 1049-54	7	24
296	Progressive Gait Deficits in Parkinson's Disease: A Wearable-Based Biannual 5-Year Prospective Study. *Frontiers in Aging Neuroscience*, **2019**, 11, 22	5.3	23
295	Rare Variants in Specific Lysosomal Genes Are Associated With Parkinson's Disease. *Movement Disorders*, **2020**, 35, 1245-1248	7	23
294	Effect of Fear of Falling on Turning Performance in Parkinson's Disease in the Lab and at Home. *Frontiers in Aging Neuroscience*, **2018**, 10, 78	5.3	23
293	Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. *Journal of Neural Transmission*, **2011**, 118, 613-9	4.3	23
292	Clinical and dual-tasking aspects in frequent and infrequent fallers with progressive supranuclear palsy. *Movement Disorders*, **2010**, 25, 1040-6	7	23
291	Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned. *Frontiers in Aging Neuroscience*, **2016**, 8, 147	5.3	23
290	Design of the Park-in-Shape study: a phase II double blind randomized controlled trial evaluating the effects of exercise on motor and non-motor symptoms in Parkinson's disease. *BMC Neurology*, **2015**, 15, 56	3.1	22
289	Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease. *Journal of Alzheimer's Disease*, **2010**, 22, 933-8	4.3	22

288	Effect of genetic variation in Kv1.3 on olfactory function. *Diabetes/Metabolism Research and Reviews*, **2009**, 25, 523-7	7.5	22
287	Sustained dopaminergic response of parkinsonism and depression in POLG-associated parkinsonism. *Movement Disorders*, **2010**, 25, 243-5	7	22
286	The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. *Journal of Neural Transmission*, **2005**, 112, 1249-54	4.3	22
285	GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia. *PLoS ONE*, **2016**, 11, e0149349	3.7	22
284	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles. *Movement Disorders*, **2020**, 35, 495-499	7	22
283	The spectrum of progressive multifocal leukoencephalopathy: a practical approach. *European Journal of Neurology*, **2019**, 26, 566-e41	6	22
282	The association between objectively measured physical activity, depression, cognition, and health-related quality of life in Parkinson's disease. *Parkinsonism and Related Disorders*, **2018**, 48, 74-81	3.6	21
281	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. *Journal of Neural Transmission*, **2016**, 123, 439-45	4.3	21
280	Is pre-motor diagnosis possible? The European experience. *Parkinsonism and Related Disorders*, **2012**, 18 Suppl 1, S195-8	3.6	21
279	Common genetic polymorphisms in moyamoya and atherosclerotic disease in Europeans. *Childs Nervous System*, **2011**, 27, 245-52	1.7	21
278	Early diagnosis of Parkinson's disease. *International Review of Neurobiology*, **2010**, 90, 81-92	4.4	21
277	Transcranial sonography reveals cerebellar, nigral, and forebrain abnormalities in Friedreich's ataxia. *Neurodegenerative Diseases*, **2011**, 8, 470-5	2.3	21
276	Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. *Movement Disorders*, **2007**, 22, 2123-6	7	21
275	Substantia nigra hyperechogenicity correlates with subtle motor dysfunction in tap dancers. *Parkinsonism and Related Disorders*, **2007**, 13, 362-4	3.6	21
274	Mild parkinsonian signs in the elderly--is there an association with PD? Crossectional findings in 992 individuals. *PLoS ONE*, **2014**, 9, e92878	3.7	21
273	Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. *Journal of Neural Transmission Supplementum*, **2006**, 123-32		21
272	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. *Movement Disorders*, **2020**, 35, 1755-1764	7	21
271	Insulin-Like Growth Factor 1 (IGF-1) in Parkinson's Disease: Potential as Trait-, Progression- and Prediction Marker and Confounding Factors. *PLoS ONE*, **2016**, 11, e0150552	3.7	21

270	Less Is More - Estimation of the Number of Strides Required to Assess Gait Variability in Spatially Confined Settings. *Frontiers in Aging Neuroscience*, **2018**, 10, 435	5.3	20
269	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. *Frontiers in Neurology*, **2017**, 8, 135	4.1	20
268	Evaluation of progression markers in the premotor phase of Parkinson's disease: the progression markers in the premotor phase study. *Neuroepidemiology*, **2013**, 41, 174-82	5.4	20
267	Retinal nerve fiber layer loss in multiple system atrophy. *Movement Disorders*, **2011**, 26, 914-6	7	20
266	Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism. *Current Neurology and Neuroscience Reports*, **2015**, 15, 43	6.6	19
265	Age- and sex-related heterogeneity in prodromal Parkinson's disease. *Movement Disorders*, **2018**, 33, 1025-1027	7	19
264	Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. *Journal of Neurology, Neurosurgery and Psychiatry*, **2013**, 84, 644-9	5.5	19
263	No evidence of association of FLJ10986 and ITPR2 with ALS in a large German cohort. *Neurobiology of Aging*, **2011**, 32, 551.e1-4	5.6	19
262	Relation of risk factors and putative premotor markers for Parkinson's disease. *Journal of Neural Transmission*, **2011**, 118, 579-85	4.3	19
261	Poor effect of guideline based treatment of restless legs syndrome in clinical practice. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 1390-5	5.5	19
260	Ultrasound in the (premotor) diagnosis of Parkinson's disease. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S429-33	3.6	19
259	Does ultrasound disclose a vulnerability factor for Parkinson's disease?. *Journal of Neurology*, **2003**, 250 Suppl 1, I24-7	5.5	19
258	Morphine in tardive and idiopathic dystonia (short communication). *Journal of Neural Transmission*, **2001**, 108, 1035-41	4.3	19
257	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy.. *Movement Disorders*, **2022**,	7	19
256	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha-synuclein profile. *Movement Disorders*, **2019**, 34, 1069-1073	7	18
255	Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease. *European Radiology*, **2011**, 21, 1962-9	8	18
254	Reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia. *Annals of Neurology*, **2001**, 49, 405-408	9.4	18
253	Cooperative genome-wide analysis shows increased homozygosity in early onset Parkinson's disease. *PLoS ONE*, **2012**, 7, e28787	3.7	18

252	Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. *PLoS ONE*, **2012**, 7, e48042	3.7	18
251	Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis. *PLoS ONE*, **2018**, 13, e0206536	3.7	18
250	Validation of a Lower Back "Wearable"-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. *Frontiers in Neurology*, **2018**, 9, 652	4.1	18
249	Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. *Movement Disorders*, **2017**, 32, 1780-1783	7	17
248	Progress of Pharmacological Approaches in Parkinson's Disease. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1106-1120	6.1	17
247	Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly. *Clinical Neurology and Neurosurgery*, **2018**, 165, 88-93	2	17
246	Digitomotography in Parkinson's disease: a cross-sectional and longitudinal study. *PLoS ONE*, **2015**, 10, e0123914	3.7	17
245	Autonomic dysfunction in subjects at high risk for Parkinson's disease. *Journal of Neurology*, **2015**, 262, 2643-52	5.5	17
244	Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. *Journal of Alzheimer's Disease*, **2013**, 34, 367-75	4.3	17
243	Age and Vascular Burden Determinants of Cortical Hemodynamics Underlying Verbal Fluency. *PLoS ONE*, **2015**, 10, e0138863	3.7	17
242	Limited Effect of Dopaminergic Medication on Straight Walking and Turning in Early-to-Moderate Parkinson's Disease during Single and Dual Tasking. *Frontiers in Aging Neuroscience*, **2016**, 8, 4	5.3	17
241	Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. *Movement Disorders*, **2016**, 31, 906-14	7	17
240	Global, Yet Incomplete Overview of Cohort Studies in Parkinson's disease. *Journal of Parkinson's Disease*, **2017**, 7, 423-432	5.3	16
239	Gait velocity and step length at baseline predict outcome of Nordic walking training in patients with Parkinson's disease. *Parkinsonism and Related Disorders*, **2015**, 21, 413-6	3.6	16
238	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. *Parkinsonism and Related Disorders*, **2015**, 21, 1427-34	3.6	16
237	Gait Is Associated with Cognitive Flexibility: A Dual-Tasking Study in Healthy Older People. *Frontiers in Aging Neuroscience*, **2017**, 9, 154	5.3	16
236	Methods in Neuroepidemiology Characterization of European Longitudinal Cohort Studies in Parkinson's Disease--Report of the JPND Working Group BioLoC-PD. *Neuroepidemiology*, **2015**, 45, 282-97	5.4	16
235	Naturally occurring alpha-synuclein autoantibodies in Parkinson's disease: sources of (error) variance in biomarker assays. *PLoS ONE*, **2014**, 9, e114566	3.7	16

234	Progressive secondary neurodegeneration and microcalcification co-occur in osteopontin-deficient mice. *American Journal of Pathology*, **2010**, 177, 829-39	5.8	16
233	Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. *Movement Disorders*, **2009**, 24, 133-7	7	16
232	Genetic analysis of heme oxygenase-1 (HO-1) in German Parkinson's disease patients. *Journal of Neural Transmission*, **2009**, 116, 853-9	4.3	16
231	Common diseases alter the physiological age-related blood microRNA profile. *Nature Communications*, **2020**, 11, 5958	17.4	16
230	EIF4G1 is neither a strong nor a common risk factor for Parkinson's disease: evidence from large European cohorts. *Journal of Medical Genetics*, **2015**, 52, 37-41	5.8	15
229	Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls. *Movement Disorders*, **2019**, 34, 1392-1398	7	15
228	Cerebrospinal fluid fatty acids in glucocerebrosidase-associated Parkinson's disease. *Movement Disorders*, **2012**, 27, 288-92	7	15
227	How precise are activities of daily living scales for the diagnosis of Parkinson's disease dementia? A pilot study. *Parkinsonism and Related Disorders*, **2013**, 19, 371-4	3.6	15
226	High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. *Alzheimer's and Dementia*, **2014**, 10, 530-540.e1	1.2	15
225	Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. *Neurobiology of Aging*, **2011**, 32, 2108.e1-5	5.6	15
224	Role of transcranial ultrasound in the diagnosis of movement disorders. *Neuroimaging Clinics of North America*, **2010**, 20, 87-101	3	15
223	Nutrition and the risk for Parkinson's disease: review of the literature. *Journal of Neural Transmission*, **2008**, 115, 703-13	4.3	15
222	Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 301-309	5.2	14
221	Reasons for mild parkinsonian signs - which constellation may indicate neurodegeneration?. *Parkinsonism and Related Disorders*, **2015**, 21, 126-30	3.6	14
220	Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?. *Frontiers in Neurology*, **2018**, 9, 500	4.1	14
219	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. *Parkinsonism and Related Disorders*, **2018**, 56, 33-40	3.6	14
218	Transcranial sonography as a diagnostic tool for Parkinson's disease: a pilot study in the city of Rio de Janeiro, Brazil. *Arquivos De Neuro-Psiquiatria*, **2011**, 69, 892-5	1.6	14
217	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. *Neurobiology of Disease*, **2009**, 35, 296-301	7.5	14

216	Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients. *Journal of Neural Transmission*, **2009**, 116, 443-50	4.3	14
215	Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse. *Movement Disorders*, **2002**, 17, 710-6	7	14
214	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. *Journal of Neurology*, **2020**, 267, 2949-2960	5.5	13
213	Decreased retinal sensitivity and loss of retinal nerve fibers in multiple system atrophy. *Graefes Archive for Clinical and Experimental Ophthalmology*, **2013**, 251, 235-41	3.8	13
212	A neurodegenerative vascular burden index and the impact on cognition. *Frontiers in Aging Neuroscience*, **2014**, 6, 161	5.3	13
211	Restless legs and substantia nigra hypoechogenicity are common features in Friedreich's ataxia. *Cerebellum*, **2011**, 10, 9-13	4.3	13
210	Transcranial sonography in the premotor diagnosis of Parkinson's disease. *International Review of Neurobiology*, **2010**, 90, 93-106	4.4	13
209	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. *Journal of Neural Transmission*, **2009**, 116, 599-605	4.3	13
208	Clock test deficits related to the global cognitive state in Alzheimer's and Parkinson's disease. *Dementia and Geriatric Cognitive Disorders*, **2012**, 33, 59-72	2.6	13
207	Nicotinic signal transduction machinery. *Journal of Molecular Neuroscience*, **2006**, 30, 149-52	3.3	13
206	Longitudinal brain atrophy distribution in advanced Parkinson's disease: What makes the difference in "cognitive status" converters?. *Human Brain Mapping*, **2020**, 41, 1416-1434	5.9	13
205	Insulin sensitivity predicts cognitive decline in individuals with prediabetes. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	13
204	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. *Movement Disorders Clinical Practice*, **2020**, 7, 750-762	2.2	13
203	Role of ANO3 mutations in dystonia: A large-scale mutational screening study. *Parkinsonism and Related Disorders*, **2019**, 62, 196-200	3.6	13
202	Biomarkers of Parkinson's disease: 20´years later. *Journal of Neural Transmission*, **2019**, 126, 803-813	4.3	12
201	Clinical, genetic, and brain sonographic features related to Parkinson's disease in Gaucher disease. *Journal of Neurology*, **2013**, 260, 2523-31	5.5	12
200	Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson's disease. *Journal of Neurology*, **2012**, 259, 1970-2	5.5	12
199	Analysis of TGFB1 in European and Japanese Moyamoya disease patients. *European Journal of Medical Genetics*, **2012**, 55, 531-4	2.6	12

198	Transcranial sonography in restless legs syndrome. *International Review of Neurobiology*, **2010**, 90, 199-215	4.4	12
197	Genetic analysis of the alpha2-macroglobulin gene in early- and late-onset Parkinson's disease. *NeuroReport*, **2000**, 11, 2439-42	1.7	12
196	Dual Tasking for the Differentiation between Depression and Mild Cognitive Impairment. *Frontiers in Aging Neuroscience*, **2016**, 8, 235	5.3	12
195	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. *Movement Disorders*, **2016**, 31, 579-83	7	12
194	The Mutation Matters: CSF Profiles of GCase, Sphingolipids, Synuclein in PD. *Movement Disorders*, **2021**, 36, 1216-1228	7	12
193	Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study. *Frontiers in Human Neuroscience*, **2019**, 13, 59	3.3	11
192	Prodromal PD: A new nosological entity. *Progress in Brain Research*, **2020**, 252, 331-356	2.9	11
191	Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. *Journal of Neuroimmunology*, **2016**, 290, 60-5	3.5	11
190	Arm swing asymmetry in overground walking. *Scientific Reports*, **2018**, 8, 12803	4.9	11
189	Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability. *Parkinsonism and Related Disorders*, **2019**, 66, 87-93	3.6	11
188	Association between vestibulo-ocular reflex suppression, balance, gait, and fall risk in ageing and neurodegenerative disease: protocol of a one-year prospective follow-up study. *BMC Neurology*, **2015**, 15, 192	3.1	11
187	Instrumented functional reach test differentiates individuals at high risk for Parkinson's disease from controls. *Frontiers in Aging Neuroscience*, **2014**, 6, 286	5.3	11
186	The Multiple Object Test as a Performance Based Tool to Assess Cognitive Driven Activity of Daily Living Function in Parkinson's Disease. *Journal of Alzheimer's Disease*, **2016**, 53, 1475-84	4.3	11
185	Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. *Movement Disorders*, **2021**, 36, 963-976	7	11
184	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. *Frontiers in Neurology*, **2018**, 9, 1123	4.1	11
183	No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs. *ADHD Attention Deficit and Hyperactivity Disorders*, **2017**, 9, 121-127	3.1	10
182	Structural brain signature of cognitive decline in Parkinson's disease: DTI-based evidence from the LANDSCAPE study. *Therapeutic Advances in Neurological Disorders*, **2019**, 12, 1756286419843447	6.6	10
181	Split-belt treadmill walking in patients with Parkinson's disease: A systematic review. *Gait and Posture*, **2019**, 69, 187-194	2.6	10

180	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. *Movement Disorders*, **2020**, 35, 1233-1238	7	10
179	Association of Plasma A□40 Peptides, But Not A□42, with Coronary Artery Disease and Diabetes Mellitus. *Journal of Alzheimer's Disease*, **2016**, 52, 161-9	4.3	10
178	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. *Alzheimer's Research and Therapy*, **2016**, 8, 42	9	10
177	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2018**, 45, 2387-2395	8.8	10
176	Life-threatening DBS withdrawal syndrome in Parkinson's disease can be treated with early reimplantation. *Parkinsonism and Related Disorders*, **2018**, 56, 88-92	3.6	10
175	SNPs in A□clearance proteins: Lower CSF A□levels and earlier onset of dementia in PD. *Neurology*, **2017**, 89, 2335-2340	6.5	10
174	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiology of Aging*, **2017**, 49, 214.e13-214.e15	5.6	10
173	Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound. *Ultrasound in Medicine and Biology*, **2010**, 36, 604-9	3.5	10
172	Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2010**, 153B, 220-8	3.5	10
171	Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors. *Dementia and Geriatric Cognitive Disorders*, **2007**, 23, 351-67	2.6	10
170	Cognitive response control in writer's cramp. *European Journal of Neurology*, **2001**, 8, 587-94	6	10
169	Lesion pattern in patients with multiple sclerosis and depression. *Multiple Sclerosis Journal*, **2000**, 6, 156-162	5	10
168	Screening for mutations in synaptotagmin XI in Parkinson's disease. *Journal of Neural Transmission Supplementum*, **2004**, 21-8		10
167	Aiming for Study Comparability in Parkinson's Disease: Proposal for a Modular Set of Biomarker Assessments to be Used in Longitudinal Studies. *Frontiers in Aging Neuroscience*, **2016**, 8, 121	5.3	10
166	The predictive power of transcranial sonography in movement disorders: a longitudinal cohort study. *Neurological Sciences*, **2018**, 39, 1887-1894	3.5	9
165	Effects of Exergaming on Attentional Deficits and Dual-Tasking in Parkinson's Disease. *Frontiers in Neurology*, **2019**, 10, 646	4.1	9
164	Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. *Sleep Medicine*, **2013**, 14, 475-81	4.6	9
163	Place value of transcranial sonography in early diagnosis of Parkinson's disease. *Neurodegenerative Diseases*, **2010**, 7, 291-9	2.3	9

162	The cold hand sign in multiple system atrophy: skin perfusion revisited. *Journal of Neural Transmission*, **2010**, 117, 475-9	4.3	9
161	Differences in substantia nigra echogenicity of nosological subtypes within the schizophrenic spectrum. A preliminary transcranial ultrasound study. *Neuropsychobiology*, **2001**, 44, 183-6	4	9
160	Clinical characteristics with an impact on ADL functions of PD patients with cognitive impairment indicative of dementia. *PLoS ONE*, **2013**, 8, e82902	3.7	9
159	Validation of Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes. *Movement Disorders*, **2021**, 36, 2663-2669	7	9
158	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 76-88	9.4	9
157	Assessment of cognitive-driven activity of daily living impairment in non-demented Parkinson's patients. *Journal of Neuropsychology*, **2020**, 14, 69-84	2.6	9
156	From Prodromal to Overt Parkinson's Disease: Towards a New Definition in the Year 2040. *Journal of Parkinson's Disease*, **2018**, 8, S19-S23	5.3	9
155	Deterioration of executive dysfunction in elderly with REM sleep behavior disorder (RBD). *Neurobiology of Aging*, **2018**, 70, 242-246	5.6	9
154	Association between cognitive impairment and urinary dysfunction in Parkinson's disease. *Journal of Neural Transmission*, **2017**, 124, 543-550	4.3	8
153	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. *Translational Neurodegeneration*, **2019**, 8, 11	10.3	8
152	Patient's perception: shorter and more severe prodromal phase in GBA-associated PD. *European Journal of Neurology*, **2019**, 26, 694-698	6	8
151	Structural Ultrasound of the Medial Temporal Lobe in Alzheimer's Disease. *Ultraschall in Der Medizin*, **2017**, 38, 294-300	3.8	8
150	Evidence for a Selectively Regulated Prioritization Shift Depending on Walking Situations in Older Adults. *Frontiers in Aging Neuroscience*, **2017**, 9, 75	5.3	8
149	Stepwise isolation of human peripheral erythrocytes, T lymphocytes, and monocytes for blood cell proteomics. *Proteomics - Clinical Applications*, **2012**, 6, 497-501	3.1	8
148	No association between NOD2 variants and Parkinson's disease. *Movement Disorders*, **2012**, 27, 1191-2	7	8
147	Substantia nigra echomorphology and motor cortex excitability. *NeuroImage*, **2010**, 50, 1351-6	7.9	8
146	Bilateral cerebral emboli monitoring during extracorporeal circulation. *Ultrasound in Medicine and Biology*, **1999**, 25, 755-8	3.5	8
145	Cerebral microembolus generation in different extracorporeal circulation systems. *Cerebrovascular Diseases*, **1999**, 9, 265-9	3.2	8

144	Patients' views on the ethical challenges of early Parkinson disease detection. *Neurology*, **2020**, 94, e2037-e2048	6.5	8
143	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. *Neurology*, **2021**, 96, e399-e411	6.5	8
142	The relation of SMI and the VSEP in a risk sample for neurodegenerative disorders. *Journal of Neural Transmission*, **2015**, 122, 1167-74	4.3	7
141	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study. *BMC Geriatrics*, **2020**, 20, 45	4.1	7
140	Parkinson disease in 2017: Changing views after 200 years of Parkinson disease. *Nature Reviews Neurology*, **2018**, 14, 70-72	15	7
139	Substantia Nigra Hyperechogenicity: Validation of Transcranial Sonography for Parkinson Disease Diagnosis in a Large Estonian Cohort. *Journal of Ultrasound in Medicine*, **2016**, 35, 17-23	2.9	7
138	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. *Movement Disorders*, **2018**, 33, 1349-1353	7	7
137	Prevalence of depressive symptoms and their association with brainstem raphe echogenicity in patients with Parkinson's disease and non-PD controls. *Psychiatry Research - Neuroimaging*, **2017**, 268, 45-49	2.9	7
136	Progression markers of motor deficits in Parkinson's disease: A biannual 4-year prospective study. *Movement Disorders*, **2017**, 32, 1254-1256	7	7
135	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. *Genetics in Medicine*, **2014**, 16, 644-5	8.1	7
134	Lowered serum amyloid-β1-42 autoantibodies in individuals with lifetime depression. *Journal of Alzheimer's Disease*, **2012**, 32, 95-100	4.3	7
133	Comprehensive association analysis of the NOS2A gene with Parkinson disease. *Neurology*, **2006**, 67, 2080-2	6.5	7
132	Evaluation of the ventricular system in children using transcranial ultrasound: reference values for routine diagnostics. *Ultrasound in Medicine and Biology*, **2004**, 30, 745-51	3.5	7
131	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. *Journal of Parkinson's Disease*, **2021**, 11, 395-404	5.3	7
130	Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. *Annals of Neurology*, **2021**, 90, E1-E12	9.4	7
129	Freezing of Swallowing. *Movement Disorders Clinical Practice*, **2016**, 3, 490-493	2.2	7
128	Substantia nigra hyperechogenicity is related to decline in verbal memory in healthy elderly adults. *European Journal of Neurology*, **2016**, 23, 973-8	6	7
127	Parkinson's disease: evolution of cognitive impairment and CSF Aβ profiles in a prospective longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 165-170	5.5	7

126	Orthostatic hypotension as a risk factor for longitudinal deterioration of cognitive function in the elderly. *European Journal of Neurology*, **2020**, 27, 160-167	6	7
125	Moderate Frequency Resistance and Balance Training Do Not Improve Freezing of Gait in Parkinson's Disease: A Pilot Study. *Frontiers in Neurology*, **2018**, 9, 1084	4.1	7
124	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. *Journal of Parkinson's Disease*, **2021**, 11, 1677-1687	5.3	7
123	Functional movement disorders in neurogeriatric inpatients : Underdiagnosed, often comorbid to neurodegenerative disorders and treatable. *Zeitschrift Fur Gerontologie Und Geriatrie*, **2019**, 52, 324-329	2.7	6
122	Moral Distress: Defined and Described by Neonatal and Pediatric Critical Care Nurses in a Quaternary Care Free-Standing Pediatric Hospital. *Dimensions of Critical Care Nursing*, **2020**, 39, 101-109	1.9	6
121	GBA-associated parkinsonism and dementia: beyond □synucleinopathies?. *European Journal of Neurology*, **2016**, 23, 520-6	6	6
120	Progression of prodromal motor and non-motor symptoms in the premotor phase study - 2-year follow-up data. *European Journal of Neurology*, **2017**, 24, 1369-1374	6	6
119	In vivo markers of Parkinson's disease and dementia with Lewy bodies: current value of the 5G4 □synuclein antibody. *Acta Neuropathologica*, **2014**, 128, 893-5	14.3	6
118	6-Hydroxydopamine leads to T2 hyperintensity, decreased claudin-3 immunoreactivity and altered aquaporin 4 expression in the striatum. *Behavioural Brain Research*, **2012**, 232, 148-58	3.4	6
117	Rotigotine in the Long-Term Treatment of Severe RLS with Augmentation: A Series of 28 Cases. *Sleep Disorders*, **2011**, 2011, 468952	1.7	6
116	LINGO1 is not associated with Parkinson's disease in German patients. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2010**, 153B, 1173-8	3.5	6
115	Transcranial sonographic findings may predict prognosis of gastroprokinetic drug-induced parkinsonism. *Parkinsonism and Related Disorders*, **2018**, 46, 36-40	3.6	6
114	Home-Based Physical Behavior in Late Stage Parkinson Disease Dementia: Differences between Cognitive Subtypes. *Neurodegenerative Diseases*, **2017**, 17, 135-144	2.3	5
113	A case of CLIPPERS syndrome responsive to tocilizumab. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e545	9.1	5
112	Movement disorders: discoveries in pathophysiology and therapy. *Lancet Neurology, The*, **2015**, 14, 9-11	24.1	5
111	Multiomics Analyses Identify Genes and Pathways Relevant to Essential Tremor. *Movement Disorders*, **2020**, 35, 1153-1162	7	5
110	The Multiple Object Test as a performance-based tool to assess the decline of ADL function in Parkinson's disease. *PLoS ONE*, **2018**, 13, e0200990	3.7	5
109	Parkinson's disease with and without preceding essential tremor-similar phenotypes: a pilot study. *Journal of Neurology*, **2014**, 261, 884-8	5.5	5

108	Maximizing the Potential of Longitudinal Cohorts for Research in Neurodegenerative Diseases: A Community Perspective. *Frontiers in Neuroscience*, **2017**, 11, 467	5.1	5
107	Cognitive profiles in Parkinson's disease and their relation to dementia: a data-driven approach. *International Journal of Alzheimer's Disease*, **2012**, 2012, 910757	3.7	5
106	Can we define "pre-motor" Parkinson's disease?. *Movement Disorders*, **2012**, 27, 595-6	7	5
105	No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease. *Movement Disorders*, **2013**, 28, 1305-6	7	5
104	Cognitive Performance Patterns in Healthy Individuals with Substantia Nigra Hyperechogenicity and Early Parkinson's Disease. *Frontiers in Aging Neuroscience*, **2016**, 8, 271	5.3	5
103	Gut Microbiome **2019**, 45-54		5
102	Effects of Levodopa on quality of sleep and nocturnal movements in Parkinson's Disease. *Journal of Neurology*, **2021**, 268, 2506-2514	5.5	5
101	Dual vs. Single Tasking During Circular Walking: What Better Reflects Progression in Parkinson's Disease?. *Frontiers in Neurology*, **2019**, 10, 372	4.1	4
100	Clinical characteristics related to worsening of motor function assessed by the Unified Parkinson's Disease Rating Scale in the elderly population. *Journal of Neurology*, **2015**, 262, 451-8	5.5	4
99	Quantitative motor assessment of dyskinesias in Parkinson's disease. *Journal of Neural Transmission* , **2015**, 122, 1271-8	4.3	4
98	Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. *Journal of Parkinson's Disease*, **2018**, 8, 455-462	5.3	4
97	Third ventricular width assessed by transcranial ultrasound correlates with cognitive performance in Parkinson's disease. *Parkinsonism and Related Disorders*, **2019**, 66, 68-73	3.6	4
96	Parenchymal imaging in movement disorders. *Frontiers of Neurology and Neuroscience*, **2015**, 36, 71-82	1.1	4
95	Tracking of striatal degeneration in prediagnostic Parkinson's disease: first steps into a promising future. *Lancet Neurology, The*, **2011**, 10, 775-6	24.1	4
94	A novel approach to dementia: high-resolution 1H MRI of the human hippocampus performed at 21.1 T. *Neurology*, **2010**, 74, 1654	6.5	4
93	Polymorphisms in the receptor for GDNF (RET) are not associated with Parkinson's disease in Southern Germany. *Neurobiology of Aging*, **2010**, 31, 167-8	5.6	4
92	Therapeutic strategies for Parkinson's disease based on data derived from genetic research. *Journal of Neurology*, **2003**, 250 Suppl 1, I3-10	5.5	4
91	Association of cognitive activities of daily living (ADL) function and nonmotor burden in nondemented Parkinson's disease patients. *Neuropsychology*, **2020**, 34, 447-455	3.8	4

90	The Hospital-Wide Implementation of Shared Decision-Making. *Deutsches Ärzteblatt International*, **2021**, 118, 225-226	2.5	4
89	Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. *Parkinsonism and Related Disorders*, **2019**, 60, 138-145	3.6	4
88	Foundations of circadian medicine.. *PLoS Biology*, **2022**, 20, e3001567	9.7	4
87	The effect of age and gender on anti-saccade performance: Results from a large cohort of healthy aging individuals. *European Journal of Neuroscience*, **2020**, 52, 4165-4184	3.5	3
86	Transcranial sonography in psychiatry as a potential tool in diagnosis and research. *World Journal of Biological Psychiatry*, **2018**, 19, 484-496	3.8	3
85	Spin turns in advanced Parkinson's disease: A new clinical gait sign?. *Parkinsonism and Related Disorders*, **2019**, 69, 19-22	3.6	3
84	Hand function is impaired in healthy older adults at risk of Parkinson's disease. *Journal of Neural Transmission*, **2014**, 121, 1377-86	4.3	3
83	A polymorphism in the gene encoding AdipoR1 affects olfactory recognition. *International Journal of Obesity*, **2011**, 35, 873-6	5.5	3
82	Redox Imbalance: In the Triad of Genetic Disturbances and Mitochondrial Dysfunction in Parkinson's Disease **2007**, 183-200		3
81	Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis.. *JAMA Neurology*, **2022**,	17.2	3
80	Enhancement of Executive Functions but Not Memory by Multidomain Group Cognitive Training in Patients with Parkinson's Disease and Mild Cognitive Impairment: A Multicenter Randomized Controlled Trial. *Parkinsons Disease*, **2020**, 2020, 4068706	2.6	3
79	Association of Ventricular Arrhythmias With Dementia: The Atherosclerosis Risk in Communities (ARIC) Study. *Neurology*, **2021**, 96, e926-e936	6.5	3
78	Everyday Function in Alzheimer's and Parkinson's Patients with Mild Cognitive Impairment. *Journal of Alzheimers Disease*, **2021**, 79, 197-209	4.3	3
77	Transcranial B-Mode Sonography in Movement Disorders. *International Review of Neurobiology*, **2018**, 143, 179-212	4.4	3
76	Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). *American Journal of Geriatric Psychiatry*, **2018**, 26, 1079-1090	6.5	3
75	Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients. *Journal of Neurology*, **2018**, 265, 1976-1984	5.5	3
74	Evaluating a Patient with Transcranial Sonography to Look for Echogenicity. *Movement Disorders Clinical Practice*, **2017**, 4, 907	2.2	2
73	Transcranial Sonography Findings in Alzheimer's Disease: A New Imaging Biomarker. *Ultraschall in Der Medizin*, **2021**, 42, 623-633	3.8	2

72	Executive Function Is Related to the Urinary Urgency in Non-demented Patients With Parkinson's Disease. *Frontiers in Aging Neuroscience*, **2020**, 12, 55	5.3	2
71	Substantia nigra hyperechogenicity in healthy controls: a [□fluoro] Dopa-PET follow-up study. *Journal of Neurology*, **2013**, 260, 1907-11	5.5	2
70	Post-cueing deficits with maintained cueing benefits in patients with Parkinson's disease dementia. *Frontiers in Neurology*, **2014**, 5, 236	4.1	2
69	Self estimated quality of life in monogenetic Parkinson's disease. *Movement Disorders*, **2011**, 26, 187-8	7	2
68	Ultrasound: not the best 'soundtrack' for a 'cannot ventilate - cannot intubate' scenario. *European Journal of Anaesthesiology*, **2012**, 29, 295; author reply 296	2.3	2
67	The regional distribution of T2-relaxation times in MR images of the substantia nigra and crus cerebri. *Neuroradiology*, **2010**, 52, 745-50	3.2	2
66	Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease. *Neurogenetics*, **2010**, 11, 203-15	3	2
65	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson□s disease. *European Journal of Neurology*, **2021**, 28, 1557-1565	6	2
64	Private variants in PRKN are associated with late-onset Parkinson's disease. *Parkinsonism and Related Disorders*, **2020**, 75, 24-26	3.6	2
63	How specific are non-motor symptoms in the prodrome of Parkinson's disease compared to other movement disorders?. *Parkinsonism and Related Disorders*, **2020**, 81, 213-218	3.6	2
62	Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia. *Neurology*, **2021**, 96, e904-e915	6.5	2
61	Bilateral vertebral artery dissection in the setting of ADEM. *Journal of the Neurological Sciences*, **2016**, 365, 212-3	3.2	2
60	Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls. *Ultrasound in Medicine and Biology*, **2019**, 45, 122-128	3.5	2
59	Prodromal features of Parkinson's disease: Self-reported symptoms versus clinically assessed signs. *Movement Disorders*, **2019**, 34, 144-146	7	2
58	Expression Profiling of Rectal Biopsies Suggests Altered Enteric Neuropathological Traits in Parkinson's Disease Patients. *Journal of Parkinson's Disease*, **2021**, 11, 171-176	5.3	2
57	Risk Disclosure in Prodromal Parkinson's Disease. *Movement Disorders*, **2021**,	7	2
56	Motor cortical excitability and paired-associative stimulation-induced plasticity in amnestic mild cognitive impairment and Alzheimer's disease. *Clinical Neurophysiology*, **2021**, 132, 2264-2273	4.3	2
55	A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. *Parkinsonism and Related Disorders*, **2021**, 90, 90-97	3.6	2

54	How to evaluate effects of occupational therapy - lessons learned from an exploratory randomized controlled trial. *Parkinsonism and Related Disorders*, **2019**, 67, 42-47	3.6	1
53	Genetik neurodegenerativer Erkrankungen. *Aktuelle Neurologie*, **2015**, 42, 385-392		1
52	Lower plasma cholesterol, LDL-cholesterol and LDL-lipoprotein subclasses in adult phenylketonuria (PKU) patients compared to healthy controls: results of NMR metabolomics investigation. *Orphanet Journal of Rare Diseases*, **2020**, 15, 61	4.2	1
51	Dual-Task Performance in GBA Parkinson's Disease. *Parkinson's Disease*, **2017**, 2017, 8582740	2.6	1
50	Cholinergic Pathway SNPs and Postural Control in 477 Older Adults. *Frontiers in Aging Neuroscience*, **2018**, 10, 260	5.3	1
49	Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. *Neurobiology of Aging*, **2009**, 30, 1706-9	5.6	1
48	Contribution of disturbed iron metabolism to the pathogenesis of Parkinson's disease. *Future Neurology*, **2008**, 3, 447-461	1.5	1
47	Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson's Disease.. *Frontiers in Aging Neuroscience*, **2021**, 13, 722830	5.3	1
46	Increased functional connectivity in a population at risk of developing Parkinson's disease. *Parkinsonism and Related Disorders*, **2021**, 92, 1-6	3.6	1
45	Neurogeriatrics-a´vision for improved care and research for geriatric patients with predominating neurological disabilities. *Zeitschrift Fur Gerontologie Und Geriatrie*, **2020**, 53, 340-346	2.7	1
44	A time-efficient screening tool for activities of daily living functions in Parkinson's disease dementia. *Journal of Clinical and Experimental Neuropsychology*, **2020**, 42, 867-879	2.1	1
43	Candidate variants in TUB are associated with familial tremor. *PLoS Genetics*, **2020**, 16, e1009010	6	1
42	Memory enhancement by multidomain group cognitive training in patients with Parkinson's disease and mild cognitive impairment: long-term effects of a multicenter randomized controlled trial. *Journal of Neurology*, **2021**, 268, 4655-4666	5.5	1
41	White Matter Hyperintensities Are Associated With Severity of Essential Tremor in the Elderly. *Frontiers in Neurology*, **2021**, 12, 694286	4.1	1
40	Cognitive impairment and sedentary behavior predict health-related attrition in a prospective longitudinal Parkinson's disease study. *Parkinsonism and Related Disorders*, **2021**, 82, 37-43	3.6	1
39	Moral distress among residents in neurology: a pilot study. *Neurological Research and Practice*, **2021**, 3, 6	3.2	1
38	Measurement of the adult human midbrain with transcranial ultrasound. *PLoS ONE*, **2021**, 16, e0247920	3.7	1
37	Complications following REM sleep behavior disorder. *Brain and Behavior*, **2021**, 11, e02129	3.4	1

36	Abnormally reduced frontal cortex activity during Trail-Making-Test in prodromal parkinson's disease-a fNIRS study. *Neurobiology of Aging*, **2021**, 105, 148-158	5.6	1
35	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis.. *Frontiers in Aging Neuroscience*, **2022**, 14, 783996	5.3	1
34	Neudefinition der Parkinson-Erkrankung. *Aktuelle Neurologie*, **2017**, 44, 260-266		0
33	A Klinefelter patient with an additional mitochondrial mutation: Implications for genotype-driven treatment and mitochondrial mutational load in different tissues and family members. *Parkinsonism and Related Disorders*, **2018**, 54, 116-118	3.6	0
32	Diagnosis of Parkinson's disease: Imaging and genetics. *Movement Disorders*, **2016**, 31, 431-2	7	0
31	Cerebrotendinous xanthomatosis. *Neurology*, **2006**, 67, E20	6.5	0
30	Autonomic Symptoms in Older Adults Are Common and Associated With Health-Related Quality of Life. *Frontiers in Neurology*, **2021**, 12, 757748	4.1	0
29	Arm swing responsiveness to dopaminergic medication in Parkinson's disease depends on task complexity. *Npj Parkinson's Disease*, **2021**, 7, 89	9.7	0
28	Krankheiten der Basalganglien. *Springer-Lehrbuch*, **2016**, 589-623	0.4	0
27	Distinct Relationship Between Cognitive Flexibility and White Matter Integrity in Individuals at Risk of Parkinson's Disease. *Frontiers in Aging Neuroscience*, **2020**, 12, 250	5.3	0
26	Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies. *Movement Disorders*, **2021**, 36, 1731-1732	7	0
25	"Cueing" for Levodopa-Induced Dyskinesias in Parkinson's Disease. *Frontiers in Neurology*, **2016**, 7, 237	4.1	0
24	LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort. *Frontiers in Neurology*, **2021**, 12, 710572	4.1	0
23	Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease. *Neurobiology of Aging*, **2021**, 109, 31-42	5.6	0
22	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.. *Npj Parkinson's Disease*, **2022**, 8, 17	9.7	0
21	Delirium on stroke units: a prospective, multicentric quality-improvement project.. *Journal of Neurology*, **2022**, 1	5.5	0
20	B-cell-depletion reverses dysbiosis of the microbiome in multiple sclerosis patients.. *Scientific Reports*, **2022**, 12, 3728	4.9	0
19	Redefinition of Parkinson□ Disease. *Neurology International Open*, **2017**, 1, E65-E70		

18	Reply to "Quantitative Motor Functioning in Prodromal Parkinson Disease". *Annals of Neurology*, **2019**, 86, 981-982	9.4
17	Mobility Deficits Assessed With Mobile Technology: What Can We Learn From Brain Iron-Altered Animal Models?. *Frontiers in Neurology*, **2019**, 10, 833	4.1
16	POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study. *Journal of Neurology*, **2012**, 259, 2232-3	5.5
15	Fundamentals of transcranial B-mode sonography57-61	
14	Neurological picture. Acute Wernicke's encephalopathy with hyperechogenic corpora mammillaria in brain sonography. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 114-5	5.5
13	Biomarkers of Alzheimer's and Parkinson's Disease **2010**, 89-117	
12	High-throughput homogeneous mass cleave assay technology for the diagnosis of autosomal recessive Parkinson's disease. *Journal of Molecular Diagnostics*, **2008**, 10, 217-24	5.1
11	Polymorphisms in the proteasomal subunit alpha4 are not associated with Parkinson's disease. *Journal of Neurology*, **2008**, 255, 441-2	5.5
10	Pathophysiology: biochemistry of Parkinson's disease **2005**, 598-611	
9	P02.360 Differences in echogenicity of substantia nigra in patients with different subtypes of the schizophrenic spectrum. *European Psychiatry*, **2000**, 15, 419s-420s	6
8	Die Parkinson-Krankheit **2004**, 200-227	
7	Transcranial Ultrasonography in Movement Disorders **2013**, 71-92	
6	In reply. *Deutsches Ärzteblatt International*, **2013**, 110, 346	2.5
5	'Cycling' with long-acting dopamine agonists for augmentation in restless legs syndrome. *European Journal of Neurology*, **2016**, 23, e17-8	6
4	'Atypical' Parkinson's disease - sporadic. *International Review of Neurobiology*, **2019**, 149, 195-206	4.4
3	Spannungsfelder als Option. *Aktuelle Neurologie*, **2018**, 45, 427-428	
2	Aktuelle Diagnose- und Therapieoptionen des Restless-Legs-Syndroms. *InFo Neurologie & Psychiatrie*, **2018**, 20, 38-46	0
1	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12223	5.2